Tervent1.5 mg/5 ml

Tervent is a selective beta-2 adrenergic agonist bronchodilator. Its uses are classified below by strength of evidence:

FDA-approved / established uses

• Bronchial asthma: Prevention and reversal of bronchospasm in patients with reversible airway obstructive disease (asthma).
• Chronic bronchitis and emphysema: Relief of bronchospasm associated with chronic obstructive pulmonary conditions where a reversible bronchospastic component is present.

Locally marketed dosage forms

• In Bangladesh, Tervent is also available as an oral syrup and as a nebulizer (respirator) solution used for acute relief of bronchospasm under medical supervision, in addition to tablet and injection forms.

Well-known off-label use (not an FDA-approved indication)

• Tocolysis (uterine relaxation) in preterm labor: Tervent has long been used off-label, in hospital settings only, to acutely relax uterine smooth muscle and delay preterm labor for a short period. Per the boxed warning, Tervent must NOT be used for prolonged tocolysis (beyond 48-72 hours) or for outpatient/oral maintenance tocolysis, due to the risk of serious maternal cardiac events and death.

Each tablet of Terbutaline Sulfate commonly contains 2.5 mg or 5 mg of terbutaline sulfate as the active ingredient, along with standard pharmaceutical excipients. Other locally available forms include oral syrup (1.5 mg/5 mL), injectable solution for subcutaneous use (1 mg/mL ampoule), and a nebulizer/respirator solution (5 mg/2 mL) for inhalation via a nebulizer device.

Tervent is the sulfate salt of terbutaline, a synthetic sympathomimetic amine that is chemically and pharmacologically related to other beta-2 selective adrenergic bronchodilators such as albuterol. It is used clinically as a bronchodilator in obstructive airway disease.

Tervent selectively stimulates beta-2 adrenergic receptors, producing relaxation of bronchial smooth muscle with comparatively less effect on beta-1 (cardiac) receptors at usual therapeutic doses, although some cardiac stimulation can still occur, especially at higher doses.

Selective beta-2 adrenergic agonist; bronchodilator (adrenergic/sympathomimetic drug class); Tervent has also historically been used off-label as a uterine relaxant (tocolytic agent).

Terbutaline Sulfate acts on beta-2 adrenergic receptors located on bronchial smooth muscle. Receptor stimulation activates the enzyme adenylate cyclase, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A, which relaxes bronchial smooth muscle and produces bronchodilation, and also inhibits the release of mediators of immediate hypersensitivity from mast cells.

At usual clinical doses, Terbutaline Sulfate preferentially stimulates beta-2 over beta-1 receptors, but this selectivity is relative and diminishes at higher doses, which is why tachycardia and other cardiac effects can still occur. The same beta-2 mediated smooth-muscle relaxation also occurs in the uterus, which is the pharmacologic basis for its historical off-label tocolytic use.

Pharmacokinetics: Onset of bronchodilator action is approximately 5-15 minutes after subcutaneous injection, 30-45 minutes after oral administration, and within a few minutes after inhalation; duration of effect is approximately 1.5-4 hours (injection) and up to 4-8 hours (oral). Terbutaline Sulfate is partially metabolized in the liver (primarily by sulfate conjugation) and excreted mainly by the kidneys, both as unchanged drug and metabolites.

Tervent tablets and syrup are taken by mouth. The injectable form is given subcutaneously only, never intravenously as a bolus, and only by or under supervision of a healthcare professional. The nebulizer/respirator solution is administered only by the inhaled route via a nebulizer device, following the physician's instructions on dilution and frequency.

The following are well-documented, clinically significant interactions with Tervent:

• Beta-blockers (e.g., propranolol): Non-selective beta-blockers can blunt or completely block the bronchodilator effect of Tervent and may provoke severe bronchospasm in asthmatic patients; concurrent use is generally avoided.
• Other sympathomimetic agents: Concurrent use with other adrenergic bronchodilators or sympathomimetics increases the risk of additive cardiovascular effects (tachycardia, arrhythmia, hypertension) and is generally not recommended.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: May potentiate the cardiovascular (pressor) effects of Tervent; use with caution, particularly within 2 weeks of MAOI use.
• Potassium-losing diuretics, theophylline, and corticosteroids: Concurrent use with Tervent increases the risk of hypokalemia (low blood potassium); potassium levels should be monitored, especially in acute, high-dose, or combined use.
• Digoxin: Tervent may be associated with decreased serum digoxin levels; the clinical significance and any resulting arrhythmia risk (especially with concurrent hypokalemia) should be monitored.

Tervent commonly causes expected pharmacologic effects related to beta-adrenergic stimulation; some effects are more serious and require prompt medical attention.

Common

• Tremor (fine skeletal muscle tremor, especially of the hands) - a very common, dose-related effect.
• Nervousness, restlessness, anxiety.
• Tachycardia (fast heart rate), palpitations.
• Headache, dizziness.
• Sweating, muscle cramps.
• Nausea, dry mouth.

Less common / serious

• Significant tachyarrhythmias or other cardiac arrhythmias, chest pain/angina - see Precautions and Warnings.
• Hypokalemia (low blood potassium) - see Precautions and Warnings.
• Hyperglycemia (raised blood sugar).
• Paradoxical bronchospasm (worsening of wheeze immediately after a dose) - rare, but requires discontinuation and alternative therapy if it occurs.
• With tocolytic use: maternal pulmonary edema and serious maternal cardiac events (see boxed warning under Contraindications and Pregnancy and Lactation).

Pregnancy (Pregnancy Category C): Animal reproduction studies have shown adverse fetal effects with Tervent, and there are no adequate, well-controlled studies in pregnant women for routine bronchodilator use. Tervent should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use in pregnancy. Boxed warning: Tervent must not be used for prolonged tocolysis (beyond 48-72 hours) or as an oral/outpatient maintenance tocolytic, because of reports of serious maternal cardiac events (including deaths) associated with such use; any tocolytic use of Tervent must be short-term and supervised by an obstetric specialist in a hospital setting.

Lactation: Tervent passes into breast milk, though nursing infants are estimated to receive only a small fraction of the maternal dose. Because effects on the nursing infant are not fully established, Tervent should be used while breastfeeding only if the expected benefit to the mother outweighs any potential risk to the infant; consult a physician.

Boxed warning - tocolytic use: Tervent should not be used for prolonged tocolysis (beyond 48-72 hours) or outpatient/oral maintenance tocolysis due to the risk of serious maternal cardiac events and death (see Contraindications and Pregnancy and Lactation).

Cardiovascular disease: Use with caution in patients with coronary artery disease, hypertension, arrhythmias, or other cardiovascular disorders, as Tervent can cause tachycardia and, rarely, more serious arrhythmias.

Diabetes mellitus: Tervent can raise blood glucose; monitor glucose control closely in diabetic patients.

Hyperthyroidism: Use with caution, as beta-adrenergic stimulation may aggravate thyrotoxic cardiovascular effects.

Hypokalemia risk: Concurrent use of potassium-losing diuretics, theophylline, or corticosteroids increases the risk of hypokalemia; monitor serum potassium, particularly with higher or combined doses.

Seizure disorders: Use with caution in patients with a history of seizures.

Paradoxical bronchospasm: If bronchospasm worsens immediately after a dose, discontinue Tervent and seek alternative therapy promptly.

Tolerance: Decreased effectiveness (tachyphylaxis) can occur with prolonged or excessive use; do not increase dose or frequency without consulting a physician.

Overdose of Tervent produces an exaggeration of its known pharmacologic effects, including marked tachycardia, palpitations, arrhythmias, angina, hypertension or hypotension, tremor, nervousness, headache, seizures, and hypokalemia.

In case of suspected overdose, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is supportive and may include cardiac monitoring and correction of electrolyte disturbances (particularly potassium) in a hospital setting; a cardioselective beta-blocker may be considered by a physician with extreme caution, as beta-blockade can worsen bronchospasm in patients with asthma. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use injectable solution if it appears discolored or contains particles.

Pediatric use: Oral Tervent is approved for use in children 12 years of age and older at the doses described under Dosage and Administration. Safety and efficacy in children under 12 years have not been formally established; use in younger children should only be under close pediatric medical supervision.

Geriatric use: Elderly patients may be more sensitive to the cardiovascular effects (tachycardia, arrhythmia) of Tervent; use with caution and monitor closely, particularly in those with pre-existing cardiovascular disease.

Renal/hepatic impairment: Specific dose-adjustment data are limited; use with caution and clinical monitoring in patients with significant renal or hepatic impairment.

Duration of Tervent therapy for asthma/bronchospasm depends on clinical response and is determined by the prescribing physician; it may be used on an as-needed basis for symptom relief or on a scheduled basis for maintenance bronchodilation, with periodic reassessment. For the off-label tocolytic use, treatment must be strictly short-term (no more than 48-72 hours) and administered only in a hospital setting under specialist supervision, per the boxed warning; Tervent must never be continued as long-term or oral maintenance tocolytic therapy.

Selective beta-2 adrenergic agonist; bronchodilator; sympathomimetic amine; (historically, off-label) tocolytic agent.

Terbutaline Sulfate selectively stimulates beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP (cAMP). This activates protein kinase A, which relaxes bronchial smooth muscle, producing bronchodilation, and also inhibits release of bronchoconstrictive mediators from mast cells. The same beta-2 receptor-mediated relaxation of smooth muscle occurs in the uterus, forming the pharmacologic basis for the historical off-label use of Terbutaline Sulfate as a tocolytic (uterine relaxant) agent. Beta-2 selectivity is only relative; at higher doses Terbutaline Sulfate can also stimulate cardiac beta-1 receptors, producing tachycardia and other cardiovascular effects.

C

Oral Tervent tablets are approved for bronchodilator use in children 12 years of age and older, dosed as described under Dosage and Administration (2.5 mg three times daily for ages 12-15 years; adult dosing from age 15 years). Safety and efficacy in children younger than 12 years have not been formally established in product labeling; use in this age group, including syrup or nebulized forms, should occur only under the direction of a pediatrician and with appropriate weight-based dosing where used in clinical practice. Children should be monitored for tremor, tachycardia, and other beta-adrenergic effects during therapy.